Our team has previously shown that L-NAME administration increases circulating levels of factors associated with preeclampsia pathogenesis, including vasoconstrictor ET-1, anti-angiogenic factor sFLT-1, and marker of inflammation, CRP [31]. The gene discussed is CRP; the disease is preeclampsia.